A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

NCT02651662 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Aggressive B-Cell Lymphoma

Interventions

DRUG: cemiplimab
DRUG: odronextamab

Sponsor

Regeneron Pharmaceuticals